4D Molecular Therapeutics Inc. Stock Price, News & Analysis

4D Molecular Therapeutics (NASDAQ: FDMT) announced key leadership changes to strengthen its late-stage clinical development capabilities. Dr. Julie Clark has been promoted to Chief Medical Officer, bringing over 20 years of retina and clinical development experience, including involvement in 10 BLA-enabling studies and six Phase 3 trials. The company also welcomed Dr. Liansheng Zhu as SVP of Biometrics and Data Quality.

The company's 4FRONT-1 Phase 3 trial for 4D-150 is progressing ahead of schedule, with enrollment completion expected in Q1 2026. Additionally, FDMT has added distinguished retina industry advisors, including Glenn P. Sblendorio, Dr. Cal Roberts, and Dr. Wiley A. Chambers, to enhance their development and commercialization expertise. Dr. Robert Kim has stepped down as Chief Medical Officer.

4D Molecular Therapeutics (NASDAQ:FDMT), a late-stage biotechnology company, has announced its participation in three major investor conferences in September 2025. The management team will engage in fireside chats and be available for one-on-one meetings at the following events:

• Cantor Global Healthcare Conference on September 4 at 11:30 a.m. ET
• H.C. Wainwright Global Investment Conference on September 9 at 10:00 a.m. ET
• Morgan Stanley Global Healthcare Conference on September 9 at 1:50 p.m. ET

Webcasts of the presentations will be available on the company's investor relations website, with archived recordings accessible for up to one year.

4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, has granted 58,900 Restricted Stock Units (RSUs) to three new non-executive employees. The compensation committee approved these inducement grants on August 12, 2025.

The RSUs were awarded under the Company's 2025 Employment Inducement Award Plan, which was established in February 2025. This plan operates under Nasdaq Global Market Rule 5635(c)(4), specifically designed for equity grants used to attract new employees to the company.

4D Molecular Therapeutics (NASDAQ:FDMT) reported Q2 2025 financial results and operational updates, highlighting significant progress in its clinical programs. The company announced an accelerated timeline for its 4D-150 Phase 3 program in wet AMD, with 4FRONT-1 data now expected in H1 2027. Additionally, positive 60-week results were presented from the 4D-150 SPECTRA trial in DME.

Key financial metrics include $417 million in cash as of June 30, 2025, expected to fund operations into 2028. Q2 2025 saw R&D expenses of $48.0 million and a net loss of $54.7 million. The company implemented a 25% workforce reduction, expected to generate annual savings of $15 million.

Clinical progress includes strong enrollment in the 4FRONT-1 trial, early initiation of 4FRONT-2, and positive DME trial results showing favorable tolerability and sustained durability. Both FDA and EMA indicated that a single successful Phase 3 study could support approval in the U.S. and Europe.

4D Molecular Therapeutics (NASDAQ:FDMT), a late-stage biotechnology company, announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. The company's management will engage in a fireside chat on Wednesday, August 13, 2025, at 2:30 p.m. ET.

The presentation will be available via webcast, and management will be available for one-on-one meetings. An archived recording of the webcast will be accessible for up to one year on the company's investor relations website.

4D Molecular Therapeutics (NASDAQ:FDMT) announced positive 60-week results from the SPECTRA clinical trial evaluating 4D-150 in diabetic macular edema (DME) patients. The Phase 3 dose (3E10 vg/eye) demonstrated significant efficacy with a 78% reduction in treatment burden compared to projected aflibercept treatment.

Key results include sustained visual acuity gains of +9.7 letters and anatomic improvement with CST reduction of -174 µm. The treatment was well-tolerated with no intraocular inflammation observed. Notably, patients receiving the Phase 3 dose required only 1.6 mean supplemental injections compared to 3.7 for lower doses and 7.0 projected for aflibercept.

Both FDA and EMA have aligned that a single Phase 3 clinical trial would be acceptable for regulatory submission for 4D-150 in DME, streamlining the path to potential approval.

4D Molecular Therapeutics (NASDAQ:FDMT) announced two upcoming presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Long Beach, CA, from July 30 – August 2, 2025.

The presentations will feature interim results from two clinical trials: the SPECTRA Phase 2a trial evaluating 4D-150 for Diabetic Macular Edema, including 52-week primary endpoint and 60-week analyses, and the PRISM Phase 2b trial evaluating 4D-150 for neovascular Age-related Macular Degeneration with 52-week results. Both presentations will be available on the company's website.

4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, has granted 4,600 Restricted Stock Units (RSUs) to one new non-executive employee on July 8, 2025. The RSUs were awarded under the Company's 2025 Employment Inducement Award Plan, which was established in February 2025 in accordance with Nasdaq Global Market Rule 5635(c)(4) to incentivize new employee recruitment.

4D Molecular Therapeutics (NASDAQ:FDMT) announced significant acceleration of its 4D-150 Phase 3 program for wet age-related macular degeneration (wet AMD). The 4FRONT-1 Phase 3 trial's topline data readout has been moved forward to H1 2027 from H2 2027, while the 4FRONT-2 Phase 3 trial was initiated ahead of schedule in June 2025.

The company implemented a 25% workforce reduction, primarily affecting early-stage R&D and support functions, expected to generate $15 million in annual cash savings. With $458 million in cash as of March 31, 2025, FDMT maintains its cash runway into 2028, supporting both Phase 3 trials, BLA preparation, and ongoing development programs in diabetic macular edema and cystic fibrosis.